Bioventus selects Pfizer as exclusive distribution partner for hip, knee OA solution in Brazil: 3 notes

Written by Shayna Korol | October 03, 2018 | Print  |

Bioventus received approval to market Durolane for hip and knee osteoarthritis in Brazil and selected Pfizer as its exclusive distribution partner.

Here are three things to know:

1. The Agência Nacional de Vigilância Sanitária granted Bioventus approval to market the single-injection joint-fluid treatment for mild to moderate hip and knee osteoarthritis.

2. Pfizer has more than 100 sales representatives throughout Brazil. The company will offer Durolane as part of its arthritis pain management portfolio.

3. According to Bioventus' CEO Tony Bihl, Brazil is the largest Latin American market for osteoarthritis pain solutions.

More articles on biologics:
Orthobiologics company completes 250 cases with OsteoCrete magnesium-based bone void filler: 3 notes
Maryland Stem Cell Research Fund awards 1st round of $8.2M funding initiative: 5 things to know
5 things to know about the global orthobiologics market

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months